IL1B and metabolic syndrome: Attenuation of pro-inflammatory cytokines such as IL-6, TNFα, and IL-1β secreted by immune cells [27, 37] and adipocytes [38, 39] may be a therapeutic approach for treating systemic low-grade chronic inflammation-associated with metabolic syndrome.